In general, the level of evidence for the interventions and information discussed in this module ranged from low to moderate. There were more studies about PCDs that focused on their functionality, but less focused on the added survival benefit, resulting in a low to moderate rating. Tourniquet replacements and conversions have more available data, although they, too, are less robust in defining the impact; but they both have a moderate level of supporting evidence. REBOA, although the level of data is increasing with time, currently maintains a low to moderate rating, while expandable intraperitoneal agents to tamponade hemorrhage are just now being explored with human clinical trials and the overall level of evidence remains low at this time.